A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel
K Hagihara, M Kazui, A Kurihara, M Yoshiike… - Drug metabolism and …, 2009 - ASPET
The efficiency and interindividual variability in bioactivation of prasugrel and clopidogrel
were quantitatively compared and the mechanisms involved were elucidated using 20 …
were quantitatively compared and the mechanisms involved were elucidated using 20 …
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with …
Aims The metabolic pathways leading to the formation of prasugrel and clopidogrel active
metabolites differ. We hypothesized that decreased CYP2C19 activity affects the …
metabolites differ. We hypothesized that decreased CYP2C19 activity affects the …
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
WC Lau, PA Gurbel, PB Watkins, CJ Neer, AS Hopp… - Circulation, 2004 - Am Heart Assoc
Background—Interindividual variability of platelet inhibition after aspirin or clopidogrel
administration has been described. Additionally, aspirin resistance and clopidogrel …
administration has been described. Additionally, aspirin resistance and clopidogrel …
Influences of different proton pump inhibitors on the anti‐platelet function of clopidogrel in relation to CYP2C19 genotypes
T Furuta, T Iwaki, K Umemura - British journal of clinical …, 2010 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Active metabolism of clopidogrel is
mainly mediated by CYP2C19. There are genetic differences in the activity of CYP2C19 …
mainly mediated by CYP2C19. There are genetic differences in the activity of CYP2C19 …
[HTML][HTML] Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Background It has been suggested that clopidogrel may be less effective in reducing the rate
of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 …
of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 …
An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma
G Tuffal, S Roy, M Lavisse, D Brasseur… - Thrombosis and …, 2011 - thieme-connect.com
Pharmacokinetic analyses of clopidogrel are hampered by the existence of multiple active
metabolite isomers (H1 to H4) and their instability in blood. We sought to retest the …
metabolite isomers (H1 to H4) and their instability in blood. We sought to retest the …
Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan
T Jinnai, H Horiuchi, T Makiyama, J Tazaki… - Circulation …, 2009 - jstage.jst.go.jp
Background: The P2Y 12 adenosine diphosphate (ADP) receptor blocker, clopidogrel, an
essential drug for the prevention of stent thrombosis after percutaneous coronary …
essential drug for the prevention of stent thrombosis after percutaneous coronary …
Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance …
AL Frelinger, DL Bhatt, RD Lee, DJ Mulford… - Journal of the American …, 2013 - jacc.org
Objectives: This study sought to determine whether known genetic, drug, dietary,
compliance, and lifestyle factors affecting clopidogrel absorption and metabolism fully …
compliance, and lifestyle factors affecting clopidogrel absorption and metabolism fully …
[HTML][HTML] Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives
Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …
[HTML][HTML] Genetic determinants of platelet response to clopidogrel
Antiplatelet agents are the mainstay treatment in the prevention and management of
atherothrombotic complications. However, a substantial interpatient variability in response to …
atherothrombotic complications. However, a substantial interpatient variability in response to …